| Literature DB >> 19213921 |
Amantha Thathiah1, Kurt Spittaels, Marcel Hoffmann, Mik Staes, Adrian Cohen, Katrién Horré, Mieke Vanbrabant, Frea Coun, Veerle Baekelandt, André Delacourte, David F Fischer, Dirk Pollet, Bart De Strooper, Pascal Merchiers.
Abstract
Deposition of the amyloid-beta peptide is a pathological hallmark of Alzheimer's disease. A high-throughput functional genomics screen identified G protein-coupled receptor 3 (GPR3), a constitutively active orphan G protein-coupled receptor, as a modulator of amyloid-beta production. Overexpression of GPR3 stimulated amyloid-beta production, whereas genetic ablation of GPR3 prevented accumulation of the amyloid-beta peptide in vitro and in an Alzheimer's disease mouse model. GPR3 expression led to increased formation and cell-surface localization of the mature gamma-secretase complex in the absence of an effect on Notch processing. GPR3 is highly expressed in areas of the normal human brain implicated in Alzheimer's disease and is elevated in the sporadic Alzheimer's disease brain. Thus, GPR3 represents a potential therapeutic target for the treatment of Alzheimer's disease.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19213921 DOI: 10.1126/science.1160649
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728